Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: a real-life experience from Belgium
peer reviewed ; Background: All-oral, interferon-free regimens that combine direct-acting antiviral drugs have significantly advanced the treatment of hepatitis C (HCV), especially for genotype 1(G1) patients. However, efficacy and safety data of interferon-free regimens in HCV genotype 4 (G4) patients are scarce. In Belgium, Sofosbuvir (SOF) and Simeprevir (SMV) treatment is available since January 2015 for G4 patients with advanced fibrosis (F3-F4 METAVIR) for 12 weeks. Methods: analysis of HCV G4 patients receiving SOF and SMV treatment in Belgium. The aim of the study was to evaluate the s... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | conference paper |
Erscheinungsdatum: | 2015 |
Verlag/Hrsg.: |
Wiley
|
Schlagwörter: | Hepatitis C / Genotype 4 / Simeprevir / Human health sciences / Gastroenterology & hepatology / Sciences de la santé humaine / Gastroentérologie & hépatologie |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27371611 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/191663 |